Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Infections Post-Transplant

Antibiotic prophylaxis with meropenem after allogeneic stem cell transplantation

Bone Marrow Transplantation volume 33, pages 183–187 (2004)Cite this article

Summary:

In the present study, we analyze the efficacy of prophylaxis with meropenem in patients receiving a matched related donor allogeneic transplant. In total, 38 patients were sequentially treated with meropenem starting on the day of the first febrile episode (n=17, group A) vs prophylactic meropenem starting on the first day with <500/mm3 granulocytes (n=21, group B), and maintained until resolution of fever or after granulocyte count >500/mm3. Of these, 16 (94%) patients in group A developed fever as compared to 16 (76%) in group B (P=0.02). While only one patient in group A did not require first-line antibiotherapy, there were seven (33%) in group B who did not require it (P=0.01) since fever lasted less than 72 h. In addition, 52% patients in group B did not require second-line antibiotics as compared to 11% among patients in group A (P=0.04). In multivariate analysis prophylaxis with meropenem (HR=2.83, 95% CI (1–8.02); P=0.04) and disease status at transplant (HR for early stage=0.15, 95% CI (0.04–0.62); P=0.04) significantly influenced the development of fever. In conclusion, the current pilot study suggests that the use of prophylaxis with meropenem during the period of neutropenia in patients undergoing allogeneic transplantation favorably affects the morbidity of the procedure by reducing febrile episodes.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Feroze Momin MD, Pranatharthi H, Chandrasekar MD . Antimicrobial prophylaxis in bone marrow transplantation. Ann Intern Med 1995; 123: 205–215.

    Article  Google Scholar 

  2. van der Meer JW, Guiot HF, van der Broek PJ, van Furth R . Infections in bone marrow transplant recipients. Semin Hematol 1984; 21: 123–140.

    CAS  PubMed  Google Scholar 

  3. Beelen DW, Haralambie E, Brandt H et al. Evidence that sustained growth supresion of intestinal anaerobic bacteria reduces the risk of acute graft versus host disease after sibling marrow transplantation. Blood 1992; 80: 2668–2676.

    CAS  PubMed  Google Scholar 

  4. Pizzo PA . Considerations for the prevention of the infectious complications in immunosuppressed patients with cancer. Rev Infect Dis 1989; 11: 1551–1563.

    Article  Google Scholar 

  5. Metcalf D . The colony stimulating factors: discovery, development, and clinical applications. Cancer 1990; 65: 1286–1295.

    Article  Google Scholar 

  6. Nemunaitis J, Rabinowe SN, Singer JW et al. Recombinant granulocyte–macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med 1991; 324: 1773–1778.

    Article  CAS  PubMed  Google Scholar 

  7. Advani R, Chao NJ, Horning SJ et al. Granulocyte–macrophage colony-stimulating factor (GM-CSF) as an adjunct to autologous hematopoietic stem cell transplantation for lymphoma. Ann Intern Med 1992; 116: 183–189.

    Article  CAS  PubMed  Google Scholar 

  8. Powles R, Smith C, Milan S et al. Human recombinant GM-CSF in allogeneic bone marrow transplantation for leukemia: double-blind, placebo-controlled trial. Lancet 1990; 336: 1417–1420.

    Article  CAS  PubMed  Google Scholar 

  9. Eric AE, Joseph L, Michael B . Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol 1998; 16: 1179–1187.

    Article  Google Scholar 

  10. Lew MA, Kehoe K, Ritz J et al. Prophylaxis of bacterial infections with ciprofloxacin in patients undergoing bone marrow transplantation. Transplantation 1991; 51: 630–636.

    Article  CAS  PubMed  Google Scholar 

  11. Maiche AG, Muhonen T . Granulocyte colony-stimulating factor (G-CSF) with or without a quinolone in the prevention of infection in cancer patients. Eur J Cancer 1993; 29: 1403–1405.

    Article  Google Scholar 

  12. Karp JE, Merz WG, Hendricksen C et al. Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1987; 106: 1–7.

    Article  CAS  PubMed  Google Scholar 

  13. Bow EJ, Rayner E, Louie TJ . Comparison of norfloxacin with cotrimoxazole for infection prophylaxis in acute leukemia. The trade-off for reduced gram-negative sepsis. Am J Med 1988; 84: 847–854.

    Article  CAS  PubMed  Google Scholar 

  14. Cruciani M, Concia E, Navarra A et al. Prophylactic cotrimoxazole versus norfloxacin in neutropenic children – perspective ramdomized study. Infection 1989; 17: 65–69.

    Article  CAS  PubMed  Google Scholar 

  15. Lew MA, Kehoe K, Ritz J et al. Ciprofloxacin versus trimethopim/sulfamethoxazole for prophylaxis of bacterial infections in bone marrow transplant recipients: a randomized, controlled trial. J Clin Oncol 1995; 13: 239–250.

    Article  CAS  PubMed  Google Scholar 

  16. Yeh SP, Hsueh EJ, Yu MS, Wang YC . Oral ciprofloxacin as antibacterial prophylaxis after allogeneic bone marrow transplantation: a reappraisal. Bone Marrow Transplant 1999; 24: 1207–1211.

    Article  CAS  PubMed  Google Scholar 

  17. Cometta A, Calandra T, Bille J, Glauser MP . Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. N Engl J Med 1994; 330: 1240–1241.

    Article  CAS  PubMed  Google Scholar 

  18. Carratalá J, Fernández-Sevilla A, Tubau F et al. Emergence of quinolone resistant Escherichia coli bacteriemia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis 1995; 20: 557–560.

    Article  PubMed  Google Scholar 

  19. Kotilainen P, Nikoskelainen J, Huovinen P . Emergence if ciprofloxacin-resistant coagulase-negative staphylococcal skin flora in immunocompromised patients receiving ciprofloxacin. J Infect Dis 1990; 16: 41–44.

    Article  Google Scholar 

  20. Kern WV, Markus A, Andriof E . Bacteriemia due to fluoro-quinolone-resistant Escherichia coli in two immunocompromised patients. Eur J Clin Microbiol Infect Dis 1994; 13: 161–165.

    Article  CAS  PubMed  Google Scholar 

  21. Kern WV, Andriof E, Oethinger M et al. Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother 1994; 38: 681–687.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Alarcón T, Pita J, López-Brea M, Piddock LJ . High-level quinolone resistance amongst clinical isolates of Escherichia coli and Klebsiella pneumoniae from Spain. J Antimicrob Chemother 1993; 32: 605–609.

    Article  PubMed  Google Scholar 

  23. Ena J, López-Perezagua MM, Martinez-Peinado C et al. Emergence of ciprofloxacin resístanse in Escherichia coli isolates after widespread use of fluoroquinolones. Diagn Microbiol Infect Dis 1998; 30: 103–107.

    Article  CAS  PubMed  Google Scholar 

  24. Schmeisser T, Kurrle E, Arnold R et al. Norfloxacin for the prevention of bacterial infection during severe granulocyto-penia after bone marrow transplantation. Scand J Infect Dis 1988; 20: 625–631.

    Article  Google Scholar 

  25. Menichetti F, Felicini R, Bucaneve G et al. Norfloxacin prophylaxis for neutropenic patients undergoing bone marrow transplantation. Bone Marrow Transplant 1989; 4: 489–492.

    CAS  PubMed  Google Scholar 

  26. Lew MA, Kehoe K, Ritz J et al. Prophylaxis of bacterial infections with ciprofloxacin in patients undergoing bone marrow transplantation. Transplantation 1991; 51: 630–636.

    Article  CAS  PubMed  Google Scholar 

  27. Krochinsky F, Wichmann G, Bornhauser M et al. Efficacy and tolerability of prophylaxic treatment with intravenous piperacillin/tazobactam in patients undergoing hematopoietic stem cell transplantation. Transplant Infect Dis 2002; 4: 132–136.

    Article  Google Scholar 

  28. Classen DC, Burke JP, Ford CD et al. Streptococcus mitis sepsis in bone marrow transplant patients receiving oral antimicrobial prophylaxis. Am J Med 1990; 89: 441–446.

    Article  CAS  PubMed  Google Scholar 

  29. Oppenheim BA, Hartley JW, Lee W, Burnie JP . Outbreak of coagulase negative staphylococcus highly resistant to ciprofloxacin in a leukemia unit. BMJ 1989; 299: 294–297.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Broun ER, Wheat JL, Kneebone PH et al. Randomized trial of the addition of gram-positive prophylaxis to standard antimicrobial prophylaxis for patients undergoing autologous bone marrow transplantation. Antimicrob Agents Chemother 1994; 38: 576–579.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Kern WV, Hay B, Kern P et al. A randomized trial of reoxithromycin in patients with acute leukemia and bone marrow transplant recipients receiving fluoroquinolone prophylaxis. Antimicrob Agents Chemother 1994; 38: 465–472.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Guiot HFL, Corel LJA, Bossen JMHJ . Prevalence of penicillin-resistant viridians streptococci in healthy children and in patients with malignant haematological disorders. Eur J Clin Microbiol Infect Dis 1994; 13: 645–650.

    Article  CAS  PubMed  Google Scholar 

  33. Orlandi E, Navarra A, Cruciani M et al. Norfloxacin versus cotrimoxazole for infection prophylaxis in granulocytopenic patients with acute leukemia. A prospective randomized study. Haematologica 1990; 75: 296–298.

    CAS  PubMed  Google Scholar 

  34. Shales DM, Gerding DN, John JF et al. Society for healthcare epidemiology of America and infectious diseases society of America joint committee on the prevention of antimicrobial resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis 1997; 25: 584–599.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Servicio de Hematología, Hospital Universitario de Salamanca, Spain

    J A Pérez-Simón, I García-Escobar, J Martinez, L Vazquez, D Caballero, C Cañizo, M V Mateos & J F San Miguel

Authors
  1. J A Pérez-Simón
    View author publications

    Search author on:PubMed Google Scholar

  2. I García-Escobar
    View author publications

    Search author on:PubMed Google Scholar

  3. J Martinez
    View author publications

    Search author on:PubMed Google Scholar

  4. L Vazquez
    View author publications

    Search author on:PubMed Google Scholar

  5. D Caballero
    View author publications

    Search author on:PubMed Google Scholar

  6. C Cañizo
    View author publications

    Search author on:PubMed Google Scholar

  7. M V Mateos
    View author publications

    Search author on:PubMed Google Scholar

  8. J F San Miguel
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to J A Pérez-Simón.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pérez-Simón, J., García-Escobar, I., Martinez, J. et al. Antibiotic prophylaxis with meropenem after allogeneic stem cell transplantation. Bone Marrow Transplant 33, 183–187 (2004). https://doi.org/10.1038/sj.bmt.1704335

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704335

Keywords

This article is cited by

Search

Advanced search

Quick links